Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Receivables: 2016-2025

Historic Change in Receivables for Cytokinetics (CYTK) over the last 9 years, with Sep 2025 value amounting to -$6.6 million.

  • Cytokinetics' Change in Receivables fell 2805.74% to -$6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 169.36%. This contributed to the annual value of $15.4 million for FY2024, which is 1252.73% up from last year.
  • Cytokinetics' Change in Receivables amounted to -$6.6 million in Q3 2025, which was down 203.19% from $6.4 million recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Change in Receivables peaked at $51.2 million during Q4 2021, and registered a low of -$50.8 million during Q1 2022.
  • Its 3-year average for Change in Receivables is $151,000, with a median of -$21,000 in 2023.
  • As far as peak fluctuations go, Cytokinetics' Change in Receivables spiked by 9,489.91% in 2021, and later plummeted by 54,103.19% in 2022.
  • Quarterly analysis of 5 years shows Cytokinetics' Change in Receivables stood at $51.2 million in 2021, then tumbled by 104.20% to -$2.1 million in 2022, then skyrocketed by 43.36% to -$1.2 million in 2023, then surged by 1,449.18% to $16.4 million in 2024, then crashed by 2,805.74% to -$6.6 million in 2025.
  • Its last three reported values are -$6.6 million in Q3 2025, $6.4 million for Q2 2025, and -$14.6 million during Q1 2025.